# A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)

> **NCT01082354** · — · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 150 (actual)

## Conditions studied

- Infant, Small for Gestational Age

## Interventions

- **DRUG:** recombinant somatropin

## Key facts

- **NCT ID:** NCT01082354
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 150 (ACTUAL)
- **Last updated:** 2016-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01082354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01082354, "A Pharmaco-epidemiological Study of Short Patients Born Small for Gestational Age (SGA), Treated With Saizen® (Recombinant Somatropin)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01082354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*